6.Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet, 2005,14(13):1745-1751.
7.DAndrea G, DAmbrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-an-ticoagulant effect of warfarin. Blood,2005,105(2):645-649.
8.Bejarano-Achache I, Levy L, Mlynarsky L ,et al. Effects of CYP4F2 polymorphism on respo- nse to warfarin during induction phase: aprospectiveopenlabel. Obser- vational cohort study [J].Clin Ther,2012,34(4):811-823.
9.Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin[J]. Br J Hosp Med(Lond), 2012,73(2):106-107.
15.Kudo T , Kawase M , Kawada S , et al. Anticoagulation after valve replacement: a multicen ter retrospective study[J].Artif Organs,1999,23(2):199-203.